Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Forma Therapeutics Partner to ID Molecular Markers for Preclinical Candidates

NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.

Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.

Through a spokesman, Forma declined to disclose the target and disease indications for the two therapeutic candidates. He added that certain details of the agreement are being finalized, but that for some projects Paradigm's PCDx test will be used, while for others, different assays could be developed.

PCDx is a next-generation sequencing-based cancer test that sequences both DNA and RNA.

Forma will also "be leveraging [Paradigm's] evidence team and biomarker expertise to develop target strategies," the spokesman said. Financial and other terms of the deal were not disclosed.

Last week Paradigm announced it initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.